Farsang C, Kapocsi J, Kiss I, Török E, Kerkovits G, Holló J, Jávor T
St.Imre Teaching Hospital, Budapest, Hungary.
Am J Hypertens. 1994 Jul;7(7 Pt 2):56S-60S. doi: 10.1093/ajh/7.7.56s.
These are the preliminary data of an open multicenter trial of antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0.63 mg twice daily) in combination with bopindolol (1.16 +/- 0.12 mg once daily; n = 30) administered for 3 years to patients with essential hypertension (WHO classification I or II). Blood pressure was significantly decreased in both treatment groups and there was no indication of resistance to therapy. Plasma levels of total cholesterol and triglycerides were decreased by the end of the second year of treatment, and there was a tendency toward increase in plasma levels of high-density lipoprotein cholesterol (HDL2 or HDL3). The atherogenic index (ratio between total cholesterol and HDL2 plus HDL3) was also decreased. Blood glucose levels remained unchanged in both normoglycemic patients and those with non-insulin-dependent diabetes mellitus (NIDDM) during 3 years of therapy. It is concluded that isradipine is safe and effective when administered long-term in the treatment of hypertensive patients with either hyperlipidemia or NIDDM.
这些是一项开放多中心试验的初步数据，该试验对原发性高血压（WHO分类I或II）患者采用伊拉地平单药治疗（剂量为每日两次，4.55±0.56毫克；n = 11）或伊拉地平（每日两次，7.5±0.63毫克）联合波吲洛尔（每日一次，1.16±0.12毫克；n = 30）进行为期3年的抗高血压治疗。两个治疗组的血压均显著降低，且没有治疗抵抗的迹象。治疗第二年结束时，总胆固醇和甘油三酯的血浆水平降低，高密度脂蛋白胆固醇（HDL2或HDL3）的血浆水平有升高趋势。动脉粥样硬化指数（总胆固醇与HDL2加HDL3的比值）也降低。在3年治疗期间，血糖正常的患者和非胰岛素依赖型糖尿病（NIDDM）患者的血糖水平均保持不变。得出的结论是，伊拉地平长期用于治疗伴有高脂血症或NIDDM的高血压患者时是安全有效的。
